Goldman Sachs analyst Salveen Richter downgraded Alnylam (ALNY) to Neutral from Buy with a price target of $173, down from $230. The firm said the Amvuttra study update suggests a limited benefit on top of standard-of-care Pfizer’s (PFE) Vyndaqel/Vyndamax, in addition to requiring additional time to improve HELIOS-B’s probability of success. Notwithstanding a positive outcome, Goldman sees a challenging outlook for the commercial outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALNY:
